BioPharmaStock
HomeAsk About StockNewsIdeasHistoryFDA DesignationsElite Program

BCDA

No price yet

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

  • BioCardia receives FDA acceptance of its De Novo pre-submission package for Helix catheter marketing clearance, with substantive review and a meeting expected this quarterOct 19, 2026
  • BioCardia presents the CardiAMP HF II trial design at the Heart Failure Society of America Annual Scientific MeetingOct 7, 2026
  • BioCardia files a revised FDA De Novo pre-submission for the Helix transendocardial delivery catheterOct 1, 2026
  • BioCardia says Japan PMDA guidance supports regulatory filing for CardiAMP cell therapy in ischemic heart failureMay 28, 2026
  • BioCardia presents CardiAMP trial data showing durable exercise and angina improvements in chronic myocardial ischemiaMay 21, 2026

    Bio Pharma Stock

    Where Science Meets Investing.

    BioPharmaStock is a specialized biopharmaceutical investment intelligence company focused exclusively on publicly traded biotechnology and pharmaceutical companies. Our research team continuously analyzes clinical trials, FDA regulatory events, scientific publications, corporate developments, and market catalysts to deliver timely research and exclusive insights for investors seeking opportunities in one of the world's most knowledge-intensive sectors.

    ALNJAM ALAALI SOFTWARE DESIGN CO. L.L.C, UAE, Abu Dhabi

    BioPharmaStock LogoBioPharmaStock Logo

    Quick Links

    • Home
    • Ask About Stock
    • News
    • Ideas
    • History
    • FDA Designations
    • Elite Program

    Contact Us

    Email: info@biopharmastock.com

    Phone: +971 50 936 3328

    Join Our Community→

    Follow Us

    Get the App

    Instant notifications on your phone

    Download on theApp StoreGet it onGoogle Play

    © 2026 Bio Pharma Stock. All rights reserved. Policy